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Persistence of antibodies to pneumococcal vaccine in patients with
chronic renal failure and renal allograft recipients. Antibody response to
the 14-valent pneumococcal capsular polysaccharide vaccine was mea-
sured by the enzyme-linked immunosorbent assay (EJA) in 17 renal
allograft recipients, 29 azotemic, II hemodialysis, and 33 control
patients. The lgG, 1gM, and IgA antibodies were measured against six
pneurnococcal antigen types 1, 3, 4, 6A, 8, and 19F. The control
patients had the best antibody responses in the lgG and IgA antibody
classes and the renal allograft recipients in the 1gM class. The renal
allograft recipients had significantly stronger antibody responses than
the azotemic and hemodialysis patients. The hemodialysis patients had
significantly weaker antibody responses than the control patients and
the renal allograft recipients, and they also lost their antibodies most
rapidly. Thus, the hemodialysis patients and probably some azotemic
patients should be considered for revaccination.
Persistance des anticorps au vaccin pneumococcique chez des insuf-
fisants rénaux chroniques. La réponse anticorps au vaccin avec Ia
capsule pneumococcique a 14 valences a été mesurée par un dosage
avec une enzyme lide a un immunoadsorbant (ELA) chez les receveurs
de 17 allogreffes rénales, chez 29 malades urémiques, chez II dialyses,
et chez 33 contrôles. Les anticorps IgG, 1gM, et IgA ont etC mesurCs
contre six types d'antigènes pneumococciques: 1, 3, 4, 6A, 8, et 19F.
Les malades contróles avaient les meilleures rCponses anticorps pour
les classes d'anticorps IgG et IgA, et les receveurs d'allogreffe rCnale
pour Ia classe des 1gM. Les receveurs d'allogreffe rCnale avaient des
reponses anticorps significativement plus fortes que les urCmiques et les
hdmodialysés. Les hémodialysés avaient des rCponses anticorps
significativement plus faibles que les malades contrOles et que les
receveurs dallogreffe rCnale, et us perdaient egalement leurs anticorps
plus rapidement. Ainsi, les hCmodialysCs, et sans doute certains
urCmiques, devraient Ctre revaccinés.
Pneumococcal infections are a major problem in patients with
chronic renal failure and in renal allograft recipients. Although
the mortality from pneumococcal infections has declined re-
markably with the advent of antimicrobial agents, the attack
rate of such infections remains virtually unchanged. Moreover,
bacteremic pneumococcal infections are associated with a high
mortality rate, which reaches 28% in patients over 50 years of
age, or who are chronically ill despite the administration of
appropriate antibiotics [I]. Different risk groups of patients
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have been vaccinated with the commercially available polyva-
lent pneumococcal capsular polysaccharide vaccine. The over-
all antibody responses have been good, but the persistence of
antibodies and the duration of protection is still unknown. The
early trials with the pneumococcal vaccine in patients with
chronic renal failure were very encouraging regarding the
antibody response. In those studies, the patients with uremia
and those with renal allograft had almost as good responses as
the healthy controls [2—5]. We have studied the antibody
response and persistence of antibodies to pneumococcal poly-
saccharide vaccine in patients with chronic renal failure and
renal allograft recipients. One of the goals of this study was to
find out whether these patients should be revaccinated with the
pneumococcal polysaccharide vaccine. We also wanted to find
out which antibody class would be the most desirable and most
responsible for the protection against pneumococcal infections.
Methods
The 14-valent pneumococcal polysaccharide vaccine
(Pneumovax®-MSD) was administered to 29 patients with
chronic renal failure not needing hemodialysis treatment, 11
hemodialysis patients, 17 patients with renal allograft, and 33
control patients. The sex distribution, the mean ages and the
age range, mean serum creatinine, and mean hemoglobin values
are given in Table 1, The vaccination with the pneumococcal
vaccine was initiated in 1980 in our hospital and since then we
have vaccinated all new renal patients with this vaccine. The
Pneumovax® was administered intramuscularly in a dose of 0.5
ml. Serum samples were taken from each patient and control
before vaccination, 4 to 6 weeks, and 12 months after vaccina-
tion. All serum samples were stored at —25°C and tested
simultaneously. The sera were assayed for antibodies to the
capsular polysaccharides of six pneumococcal types 1, 3,4, 6A,
8, and 19F. The purified pneumococcal polysaccharides were
prepared and provided by Merck Sharp & Dohme Research
Laboratories (West Point, Pennsylvania, USA). The enzyme
immunoassay (EIA) method is described in detail by Koskela,
Leinonen, and Luotonen [6]. The titers were expressed as
dilutions of serum giving 0.3 absorbence units (405 nm). For the
statistical analysis, the natural logarithms of the mean titers
were used.
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Table 1. Selected characteristics of renal patients and controls immunized with pneumococcal vaccine
Study group N Females Males
Mean
age
Age
range
Mean KREA
i.moleIliter
Mean HB
giliter
Controls 33 14 19 56.6 33 to 73 90.6 148
Azotemic 29 13 16 54.1 18 to 73 422 120
Hemodialyzed II 4 7 48.2 33 to 64 1287 85
Allograft 17 6 11 36.1 19 to 67 176 134
Table 2. Geometric mean antibody titers against six different pneumococcal polysaccharide antigens in the azotemic (AZO), hemodialysis
(HEM), renal allograft recipients (ALL), and control (CON) patients before (0), 4 to 6 weeks (I), and 12 months (II) after vaccination.
Comparisons between the patient group pairs are indicated by letters
Type I Type 3 Type 4
IgG dGMT 1gM dGMT IgA dGMT IgG dGMT 1gM dGMT IgA dGMT IgG dGMTIgMdGMT IgA dGMT
CON 0 l160 9 60de 480 110 120 2140' 250° l40
1 2200 1.9 180 2.0 320 5.3 770 1.6 130 1.2 200 1.6 4290 2.6 350 1.4 550 3.9
111630 1.4 100 1.1 150 2.5 590 1.2 90 0.8 140 1.1 2950 1.4 250 1.0 300 2.1AZO 0 b 150 50df8 460 110 90 2120 380 l40s
11760 1.8 220 1.5 160 3.2 640 1.4 110 1.0 160 1.8 3360 1.6 440 1.2 310 2.2
111170 1.2 140 0.9 60 1.2 490 1.1 80 0.7 90 1.0 2050 1.0 360 0.9 190 1.4
HEM 0 3l0a 70c 4Øefl. 5401k 50 110 8401m 170'P 60
I 830 2.7 90 1.3 80 2.0 530 1.0 70 1.4 170 1.5 1270 1.5 200 1.2 180 3.0
II 370 1.2 90 1.3 70 1.8 390 0.7 50 1.0 180 1.6 660 0.8 130 0.8 160 2.7
ALL 0 830 120 50" 480k 100 80 1780 350" 80
11670 2.0 250 2.1 220 4.4 940 2.0 150 1.5 170 2.1 3210 1.8 560 1.6 370 4.6
111140 1.4 170 1.4 110 2.2 540 1.1 90 0.9 100 1.3 2080 1.2 430 1.2 170 2.1
b, c, i, m, n, o, p, r, s: P< 0.05;a, d, e,f,g, h, k,1: P< 0.005
Type 6A Type 8 Type 19F
IgG dGMT 1gM dGMT IgA dGMT IgG dGMT 1gM dGMT IgA dGMT IgG dGMT 1gM dGMT IgA dGMT
CON 0 1930' 250 I205 1490° 250H 90MN 1120RS 170 90''
I 3550 1.8 320 1,3 300 2.5 3050 2.0 360 1.4 480 5.3 2230 2.0 230 1.4 260 2.9
II 2640 1.4 230 0.9 190 1.6 2300 1.5 230 0.9 240 2.7 1640 1.5 180 1.0 170 1.9
AZO 0 1550" 310 70zB 1750EF 160JK 60MOP 1020T 240
12160 1.4 370 1.2 150 2.1 2650 1.5 200 1.3 150 2.5 1560 1.4 330 1.4 170 2.1
111730 1.1 310 1.0 90 1.3 1830 1.0 160 1.0 80 1.3 1280 1.1 190 0.8 80 1.0
HEM 0 600tU 190" 60yzA 1130DEG 60HJL 50N0Q 280RT 130
I 940 1.6 170 0.9 70 1.1 2310 2.1 70 1.3 70 1.4 530 1.9 150 1.2 80 1.3
II 620 1.0 170 0.9 110 1.8 570 0.5 80 1.3 100 2.0 420 1.5 100 0.8 60 1.0
ALL 0 1460" 360" 70A 1430FG 140KL 50PQ 760S 130 SO
12420 1.7 510 1.4 220 3.1 2750 1.9 310 2.2 310 6.2 1430 1.9 190 1.5 120 2.4
111850 1.3 460 1.3 110 1.6 1790 1.3 240 1.7 160 3.2 1130 1.5 150 1.2 60 1.2
u, v, x, y, z, B, F, J, 0, S, T, U: P <0.05; t, A, K, L, P. R, V. X: P <0.005; D, E, G, H, M, N, Q: P <0.001 by the2-factoranalysis ofvariance.
dGMT: fold increase in geometric mean titers between the sera 0 and I and 0 and II, respectively.
Statistical methods
The differences between the patient groups were analyzed
using the 2-factor analysis of variance with repeated measures.
The correlation of antibody titers to the clinical parameters of
the patient groups was analyzed using the one-way analysis of
covariance.
Results
The EIA antibody titers against the types 1, 3, 4, 6A, 8, and
19F pneumococcal polysaccharide antigens were analyzed sep-
arately for IgG, 1gM, and IgA class-specific antibodies. The
results are given in Table 2 and Figures 1 through 3. The control
patients had the highest post-vaccination mean IgG titers
against all but type 3 antigens (Fig. 1, Table 2). On the other
hand, the hemodialysis patients had very low pre-vaccination
titers and the antibody response was lower than in all the other
patient groups. The azotemic patients had higher pre- and
post-vaccination IgG antibody titers than the allograft recipi-
ents against antigen types 1, 4, and 19F, and to the other types
the titers were very close to each other. When the antibody
responses were expressed as antibody increase between the
pre- and post-vaccination antibody titers, the results were very
similar, but the hemodialysis patients had the strongest rise in
titers against types 1 and 8 due to the low pre-vaccination level
(Table 2). When the IgG antibody titers were compared 12
months after vaccination in different groups, the control pa-
tients had the most stable antibody levels and the hemodialysis
patients had the most rapid fall in titers. The IgG antibody
levels of the azotemic patients and the renal allograft recipients
were very close to each other. When the antibodies and changes
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Fig. 2. Geometric mean 1gM antibody titers
expressed as natural logarithms against six
different pneumococcal polysaccharide
antigens in the azotemic, hemodialysis,
renal allograft recipients, and control
patients before (0), 4 to 6 weeks (I) and 12
months (II) after pneumococcal
vaccination. Symbols same as Fig. I.
in titers were compared to each other, the control patients
differed significantly from the hemodialysis patients for type 3
(P < 0.05), for types 1, 4, 6A, 19F (P < 0.005), and for type 8
antibodies (P <0.001). Also, the azotemic patients had signif-
icantly better response and persistence of antibody levels than
the hemodialysis patients for type 1, 4, 6A, 19F (P < 0.05) and
type 8 antigens (P < 0.001).
The 1gM antibody responses in the different patient groups
and the controls are given in Table 2 and Figure 2. In this
analysis, the renal allograft recipients had the best 1gM anti-
body responses against types 1, 3, 4, and 6A antigens. The
control patients had the best responses against type 8, and the
azotemic patients against type 19F antigens. The hemodialysis
patients had the poorest 1gM antibody responses for all different
antigen types. The renal allograft recipients had the strongest
increases in antibody titers against all antigen types (Table 2).
When the antibody levels and changes in titers were compared,
the hemodialysis patients differed significantly from the con-
trols for types 1 and 4 (P < 0.05) and type 8 (P < 0.001). The
renal allograft recipients had significantly stronger 1gM anti-
body responses than the hemodialysis patients for types 4, 6A,
(P < 0.05), and 8 (P < 0.005) antigens.
The IgA antibody responses to the different antigen types are
expressed in Table 2 and Figure 3. Here the control patients had
the highest pre- and post-vaccination mean antibody titers for
all antigen types. The renal allograft recipients had the second
best responses for type 1, 4, 6A, and 8 antigens. And again, the
hemodialysis patients had the lowest antibody responses for all
antigen types except type 3. The controls and the renal allograft
recipients had the strongest increases in antibody titers against
most of the antigen types (Table 2). When these antibody
responses and changes in titers were compared, the control
patients differed significantly from the hemodialysis patients for
type 6A (P < 0.05), type 1 and 19F (P < 0.005), and for type 8
(P < 0.001). The control patients also differed significantly from
the azotemic patients for type 4, 6A, and 19F (P < 0.05), for 1
(P <0.005), and for type 8 (P < 0.001).
When the persistence of antibodies was studied by comparing
the ratio of geometric mean titers 12 months after vaccination in
different groups to the corresponding pre-vaccination titer of
the controls, the differences between the patient groups were
clear (Table 3). The controls had the highest IgG ratios, the
renal allograft recipients had the second highest, and the
hemodialysis patients had the lowest ones. In 1gM antibodies,
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Table 3. Ratio of the geometric mean antibody titers of the renal patients and controls 12 months after vaccination to the corresponding
pre-vaccination titer of the controls
Patient group Antibody class
Antigen type
Type I Type 3 Type 4 Type 6A Type 8 Type 19F
CON IgG 1.4 1.2 1.4 1.4 1.5 1.5
AZO 1.0 1.0 1.0 0.9 1.2 1.1
HEM 0.3 0.8 0.3 0.3 0.4 0.4
ALL 1.0 1.1 1.0 1.0 1.2 1.0
CON 1gM 1.1 0.8 1.0 0.9 0.9 1.0
AZO 1.6 0.7 1.4 1.2 0.6 1.1
HEM 1.0 0.5 0.5 0.7 0.3 0.6
ALL 1.9 0.8 1.7 1.7 1.0 0.9
CON IgA 2.5 1.1 2.1 1.6 2.7 1.9
AZO 1,0 0.8 1.4 0.8 0.9 0.9
HEM 1.2 1.4 1.1 0.9 1.1 0.7
ALL 1.8 0.8 1.2 0.9 1.8 0.7
Abbreviations same as Table 2.
the renal allograft recipients had the highest ratios for types 1,
4, 6A, and 8, the azotemic patients the second highest for types
1,4, 6A, and 19F, and the hemodialysis patients had the lowest
ratios against all types. In IgA antibodies, the controls had the
highest ratios against all except type 3 and the renal allograft
recipients the second highest ratios for types 1 and 8. The
azotemics and the hemodialysis patients were quite close to
each other.
When the antibody responses were correlated to the kidney
function, the antibody response was significantly lower in IgG
type 2 and 8 (P < 0.05), in IgA type 1, 6A, 19F (P < 0.05), and
8 (P < 0.005) when the serum creatinine increased. When the
persistence of the antibody levels was correlated to the kidney
function, the fall in antibody titers was stronger in IgG type 1 (P
<0.05) and 8 (P < 0.001) and in 1gM type 1 and 6A (P <0.05)
when the serum creatinine increased.
When the age of the patients was correlated to the antibody
response, with increasing age the antibody response was lower
in IgG type 1 and 19F (p < 0.05), in 1gM type 1 and 8 (P < 0.05)
and in IgA type 1, 4, 6A, 19F (P < 0.05), and 3 (P < 0.001).
Also, with increasing age the fall in antibody titers was faster in
IgG type 3 (P < 0.05) and 19F (P < 0.005), and weaker in 1gM
type 6A and 8 (P < 0.05), in IgA type 1, 3, and 4 (P < 0.05), and
in 6A (P < 0.005).
Discussion
The indications for pneumococcal vaccination have been
clearly settled during the recent years. The candidates for
vaccination are those who have an increased risk for
pneumococcal infections. This includes patients who are sched-
uled for splenectomy or have had splenectomy. Also, patients
with diabetes and chronic renal failure and renal allograft
recipients are at high risk for pneumococcal infections [7—8].
The patients with insulin-dependent diabetes respond ade-
quately to the pneumococcal vaccination [9]. The splenecto-
mized patients have been observed to have impaired immune
response to the polyvalent pneumococcal vaccine [10, 11].
Thus, the vaccination should be given before a planned sple-
nectomy, especially in patients with Hodgkin's disease [121.
There are groups of patients who have an increased risk for
pneumococcal infections, such as patients with multiple
myeloma, but the antibody response in these patients has been
poor and without any protective effect [13—151. The protective
effect of pneumococcal vaccination is probably not very good
and long-lasting because pneumococcal diseases have been
observed in vaccinated patients 1 to 18 months after vaccination
[161. There are several reports of pneumococcal vaccination in
patients with chronic renal disease and renal allograft recipients
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Fig. 3. Geometric mean IgA antibody titers
expressed as natural logarithms against six
different pneumococcal polysaccharide
antigens in the azotemic, hemodialysis,
renal allograft recipients, and control
patients before (0), 4 to 6 weeks (I) and 12
months (II) after pneumococcal vaccination.
Symbols same as Fig. 1.
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with somewhat conflicting results. Overall, the antibody re-
sponses in the hemodialysis patients have been quite good; in
some series, even better than those of the renal allograft
recipients [5, 17]. In these studies, however, only the total and
not the class-specific antibody response had been determined.
We have studied the antibody responses to 14-valent
pneumococcal polysaccharide vaccine in patients with chronic
renal failure, either hemodialyzed or not, and in renal allograft
recipients. The antibody responses were analyzed for IgG, 1gM,
and IgA antibody classes for the types 1, 3, 4, 6A, 8, and 19F
polysaccharide antigens. From these pneumococcal types, 3,
6A, and 19F are relatively common, and types 1, 4, and 8 rare,
but cause serious infections in humans [18, 19]. The differences
between the patient groups were very clear; the controls and
the renal allograft recipients had the best and the hemodialysis
patients had the poorest antibody responses. However, the
hemodialysis patients had a good response to vaccination when
measured by increase in titer, but the antibody levels were low
and decreased very rapidly. In IgG antibodies, the control
patients had the best responses for all except type 3 and for IgA
antibodies for all antigen types. However, in 1gM antibodies the
renal allograft recipients had the best responses for all except
two (8 and l9F) antigen types. This is an interesting finding that
suggests that the immunosuppressive treatment given to the
renal transplant recipients modifies the antibody response
toward a primitive direction. The hemodialysis patients had the
poorest antibody responses in all antibody classes and to almost
all antigen types.
The antibody response correlated clearly to the kidney func-
tion and to the age of the patients. With increasing serum
creatinine, the rise in IgG and IgA antibodies was lower for
several antigen types. With increasing age, the rise in IgG, 1gM,
and IgA antibodies was lower, and the decline in IgG antibodies
was faster for some antigen types. There were some variations
between the different antigen types, type 3 giving the weakest
and type 8 giving the strongest differences between the patient
groups. On the basis of these results we cannot yet conclude
which antibody class would be the most protective and most
desirable, but the IgG and IgA antibodies correlated best to the
kidney function. As to the protective effect of these antibodies,
none of our patients has had any diagnosed pneumococcal
infections during the observation time.
There are reports of side effects of pneumococcal vaccination
in which the younger patients had more local and systemic
adverse effects after vaccination than the older ones. Our
patients received the pneumococcal vaccination intramuscu-
larly and, according to Pönkä and Leinonen [20], the patients
receiving the vaccine subcutaneously had fewer side effects.
There are very little data available about the duration of the
protective effect against serious pneumococcal infections after
vaccination. The original recommendation was not to revac-
cinate patients sooner than 5 yrs after the primary vaccination
because of possible local and systemic side effects of the
vaccine. The newest published recommendation is not to revac-
cinate at all [21]. In the present study, the IgG class antibodies
had declined to the pre-vaccination level already 1 yr after
vaccination in the hemodialysis patients and also in some
azotemic patients, especially in the older ones. There were,
however, some differences between the antigen types. Also, the
antibody levels of the hemodialysis patients were clearly below
the corresponding pre-vaccination titers of the controls, sug-
gesting that there would be no protection left at all 1 yr after
vaccination. In the 1gM and IgA class antibodies this difference
was not so clear. As to the protection against pneumococcal
infections, probably the IgG class antibodies are the most
important ones because they are known to promote the opsono-
phagocytosis more efficiently than the 1gM class antibodies.
The protective role of the serum IgA class antibodies against
pneumococcal infection is poorly documented. It is not known
whether the pneumococcal vaccination stimulates production
of secretory IgA class antibodies to pneumococcal antigens,
which might play an important role in the protection against
infections. Because in this study the lgG class antibodies
correlated best to the kindey function and to the other clinical
parameters, it seems that this antibody class might play the
most important role in the protection against serious
pneumococcal infections.
On the basis of the present results, it seems that the
hemodialysis patients and probably some azotemics, especially
the older ones, should be revaccinated with the new 23-valent
pneumococcal vaccine. We presently recommend routine vac-
cination of all renal patients with polyvalent pneumococcal
vaccine because there were no side effects in the present patient
material. It seems that early in illness the patients have a better
antibody response. All renal patients are potential candidates
for future kidney transplantation; thus, it should be preferable
to vaccinate them all well before transplantation since the
immunosuppressive treatment given after transplantation might
modify the antibody response. The same recommendation has
been given recently by the Centers for Disease Control [21].
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